A phase II study of the potent PARP inhibitor, rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation.

Authors
Plummer, R
Lorigan, Paul C
Steven, N
Scott, L
Middleton, M
Wilson, R
Mulligan, E
Curtin, N
Wang, D
Dewji, R
Abbattista, A
Gallo, J
Calvert, H
Affiliation
Institute for Cancer Research, Paul O'Gorman Building, Newcastle University, Framlington Place, Newcastle upon Tyne NE2 4HH, UK. ruth.plummer@ncl.ac.uk
Issue Date
2013-05

Metadata
Show full item record
Abstract
poly(ADP ribose) polymerase inhibition has been shown to potentiate the cytotoxicity of DNA damaging agents. A phase I study of rucaparib and temozolomide showed that full-dose temozolomide could be given during PARP inhibition. We report the results of a phase II study of intravenous rucaparib 12 mg/m(2) and oral temozolomide 200 mg/m(2) on days 1-5 every 28 days in patients with advanced metastatic melanoma.
Citation
A phase II study of the potent PARP inhibitor, rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation. 2013, 71 (5):1191-9 Cancer Chemother Pharmacol
Journal
Cancer Chemotherapy and Pharmacology
URI
http://hdl.handle.net/10541/295488
DOI
10.1007/s00280-013-2113-1
PubMed ID
23423489
Type
Article
Language
en
ISSN
1432-0843
Collections